Analysts forecast that AtriCure, Inc. (NASDAQ:ATRC) will post sales of $45.27 million for the current quarter, according to Zacks. Three analysts have issued estimates for AtriCure’s earnings, with the lowest sales estimate coming in at $44.90 million and the highest estimate coming in at $46.00 million. AtriCure posted sales of $41.16 million in the same quarter last year, which suggests a positive year-over-year growth rate of 10%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that AtriCure will report full-year sales of $45.27 million for the current year, with estimates ranging from $174.70 million to $177.10 million. For the next fiscal year, analysts expect that the business will post sales of $195.37 million per share, with estimates ranging from $194.10 million to $197.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for AtriCure.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. AtriCure had a negative net margin of 19.40% and a negative return on equity of 20.28%. The company had revenue of $42.20 million during the quarter, compared to analysts’ expectations of $43.44 million. During the same period in the prior year, the company posted ($0.21) earnings per share. AtriCure’s revenue for the quarter was up 10.1% compared to the same quarter last year.

Several equities research analysts have recently weighed in on ATRC shares. Zacks Investment Research cut shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Canaccord Genuity reiterated a “buy” rating and set a $28.00 price objective on shares of AtriCure in a research report on Monday, October 9th. Needham & Company LLC decreased their price objective on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. ValuEngine cut shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Finally, TheStreet cut shares of AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $25.00.

Shares of AtriCure (ATRC) opened at $17.90 on Wednesday. AtriCure has a 12-month low of $14.78 and a 12-month high of $25.18. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28.

In other AtriCure news, CFO M. Andrew Wade sold 2,000 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $18.41, for a total value of $36,820.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director B Kristine Johnson purchased 1,500 shares of AtriCure stock in a transaction on Wednesday, November 8th. The stock was bought at an average price of $18.36 per share, with a total value of $27,540.00. Following the completion of the acquisition, the director now directly owns 10,969 shares of the company’s stock, valued at approximately $201,390.84. The disclosure for this purchase can be found here. Company insiders own 11.90% of the company’s stock.

A number of large investors have recently bought and sold shares of ATRC. Rhumbline Advisers grew its holdings in shares of AtriCure by 0.4% during the second quarter. Rhumbline Advisers now owns 36,056 shares of the medical device company’s stock valued at $874,000 after buying an additional 130 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of AtriCure by 3.8% during the second quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock valued at $208,000 after buying an additional 312 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of AtriCure by 7.9% during the second quarter. Voya Investment Management LLC now owns 17,158 shares of the medical device company’s stock valued at $416,000 after buying an additional 1,250 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of AtriCure by 1.7% during the second quarter. Teachers Advisors LLC now owns 78,341 shares of the medical device company’s stock valued at $1,900,000 after buying an additional 1,321 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in shares of AtriCure by 4.3% during the second quarter. California Public Employees Retirement System now owns 36,100 shares of the medical device company’s stock valued at $875,000 after buying an additional 1,500 shares during the last quarter. Institutional investors and hedge funds own 86.17% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “AtriCure, Inc. (ATRC) Expected to Post Quarterly Sales of $45.27 Million” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/06/atricure-inc-atrc-expected-to-post-quarterly-sales-of-45-27-million.html.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Get a free copy of the Zacks research report on AtriCure (ATRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.